Division of Public Health, University of Liverpool, Liverpool, UK.
Epilepsy Behav. 2011 Jul;21(3):255-60. doi: 10.1016/j.yebeh.2011.04.002. Epub 2011 May 14.
We assess the psychometric properties of a revised stigma scale and report the levels of stigma in an incident population and the clinical, demographic, and quality-of-life factors associated with doing so. A total of 1566 people with new-onset epilepsy completed the revised stigma scale, as part of the Standard and New Antiepileptic Drugs (SANAD) trial. The revised scale had good internal consistency (0.85) and good concurrent validity. It also reduced the floor and ceiling effects associated with the original scale. Fifty-four percent of people reported feeling stigmatized (47.3% mild-moderate stigma, 6.1% high stigma). Reduced sense of mastery, younger age (<50), side effects of medication, poorer cognitive function, feeling socially restricted, poor global quality of life, and more than four seizures at baseline were significant factors determining scores on this revised scale. These should be the focus of interventions to try and reduce feelings of stigma in those with new-onset epilepsy.
我们评估了修订后耻辱感量表的心理测量特性，并报告了新发癫痫人群的耻辱感水平，以及与之相关的临床、人口统计学和生活质量因素。共有 1566 名新发癫痫患者完成了修订后的耻辱感量表，这是标准和新抗癫痫药物（SANAD）试验的一部分。修订后的量表具有良好的内部一致性（0.85）和良好的同时效度。它还减少了原始量表的地板效应和天花板效应。54%的人报告感到被歧视（47.3%轻度至中度歧视，6.1%高度歧视）。较低的掌控感、较年轻（<50 岁）、药物副作用、认知功能较差、感到社交受限、整体生活质量较差以及基线时有超过四次发作是决定修订后量表得分的重要因素。这些应该是干预的重点，以试图减少新发癫痫患者的耻辱感。
